Welcome

Consolidate your knowledge of weight management in type 2 diabetes (T2D) and explore:

• The epidemiology, burden and long-term complications associated with T2D
• Current treatment options and new drugs for T2D
• Lifestyle and pharmacological strategies for T2D prevention, weight control and loss
• Factors to consider when choosing T2D treatments
• The importance of patient-centred communication and patient involvement in weight management
• Videos featuring Professor Caroline Apovian discussing weight management in T2D

Meet the experts

Meet our leading expert Professor Caroline Apovian, providing you with your digital learning experience via short integrating digestible videos. Professor Apovian is a leading weight management researcher and has held a position at the forefront of the obesity and nutrition fields for over thirty years.

Introduction to Professor Caroline Apovian

Professor Caroline Apovian

Caroline M. Apovian, MD, FACP, FTOS, DABOM is Co-Director of the Center for Weight Management and Wellness (CWMW) in the Division of Endocrinology, Diabetes, and Hypertension at Brigham and Women’s Hospital and is a Professor of Medicine at Harvard Medical School. As well as being one of the world’s leading weight management experts, she is also a healthcare provider, teacher, New York Times bestselling author and one of the founding creators of the American Board of Obesity Medicine. Professor Apovian’s current research interests include weight change and its effects on adipose tissue metabolism and inflammation, obesity and cardiovascular disease, resolution of type 2 diabetes and cardiovascular disease in the bariatric surgery population, disparities in the treatment of obesity in underserved populations, and novel pharmacotherapeutic agents for the treatment of obesity.

Disclosures: Professor Apovian has participated on advisory boards for Abbott Nutrition, Allergan, Inc., Altimmune, Inc., Cowen and Company, LLC, Curavit Clinical Research, EnteroMedics, EPG Communication Holdings Ltd, Gelesis, SRL Pharma, Jazz Pharmaceuticals, Inc., L-Nutra, Inc., NeuroBo Pharmaceuticals, Inc., Novo Nordisk, Inc., Pain Script Corporation, Real Appeal, Riverview School, Rhythm Pharmaceuticals, Roman Health Ventures, Inc., Scientific Intake Ltd. Co., Tivity Health, Inc., Xeno Biosciences and Zafgen Inc. She has received research funding from NIH, PCORI, Novo Nordisk and GI Dynamics, Inc.

Professor Melanie Davies

Professor Melanie Davies is Professor of Diabetes Medicine at the University of Leicester and an Honorary Consultant Diabetologist at the University Hospitals of Leicester NHS Trust. She is the Co-Director of the Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust. Professor Davies’ research interests include the causes, screening, prevention, self-management and treatment of type 2 diabetes mellitus. She is a National Institute for Health Research Senior Investigator Emeritus, Director of the NIHR Leicester Biomedical Research Centre and co-chair of EASD/ADA’s Consensus Report on T2DM Management. She has published over 800 original articles and has received over £86M of grant funding. She was awarded the CBE (Commander of the Most Excellent Order of the British Empire) in the 2016 New Year’s Honour’s List for services to diabetes research. 

Disclosures: Professor Davies has received grants/research support from AstraZeneca and Novo Nordisk and honoraria or consultation fees from Lilly, Boehringer Ingelheim and Novo Nordisk. She has participated in company sponsored speaker bureaus for Lilly, Boehringer Ingelheim, Novo Nordisk, AstraZeneca, Napp Pharmaceuticals, Novartis, Sanofi and Medtronic.

Professor Rachel Batterham

Professor Rachel Batterham is Professor of Obesity, Diabetes and Endocrinology at University College London (UCL) and Honorary Consultant at University College London Hospital (UCLH). She is the Director for the UCLH/UCL NIHR Biomedical Research Centre Obesity Research Them and leads the UCL Centre for Obesity Research. She has made significant clinical contributions to defining the management of patients living with obesity through her membership of the NICE Obesity Guideline Development Group. She is the Royal College of Physicians’ Special Advisor on Obesity and is co-chair of NHS England’s Clinical Advisory Group for specialist weight management. Her research has played a critical role in gut hormones being developed as treatments for obesity and her papers have been cited more than 26,000 times. 

Disclosures: Professor Batterham has received grants/research support from Novo Nordisk and Rhythm Pharmaceuticals and honoraria or consultation fees from Novo Nordisk, Gila Therapeutics Ltd, Epitomme Medical Ltd, Eli Lilly, Pfizer and ViiV. She has participated in company sponsored speaker bureaus for Novo Nordisk, ViiV and Eli Lilly.